Growing evidence indicates that a non-coding RNA named miR-34b/c plays crucial roles in carcinogenesis, and its common polymorphism, pri-miR-34b/c rs4938723, also participates in this process and is associated with cancer susceptibility. However, this association was previously undefined and ambiguous. Therefore, we carried out an updated analysis to evaluate this relationship between rs4938723 polymorphism and cancer susceptibility.
Background
Cancer is a leading cause of death worldwide. To make things worse, the number of cancer cases and deaths is expected to grow rapidly with increase in populations, age, and adaptation to lifestyle behaviors that increase cancer risk [1] . One of the major reasons for variability among individuals is the presence of single-nucleotide polymorphisms (SNPs), which makes individuals more susceptibility to cancer [2] . Several explorations related to genome-wide associations have suggested there are many loci in the genome that have signs of low tumor susceptibility for common tumors [3] [4] [5] .
MicroRNAs (miRNAs) are a type of single-stranded non-encoded small RNA that can inhibit the transcription of mRNA or promote its degradation at the post-transcription level by binding to the target mRNA 3' UTR region to regulate gene expression [6, 7] . There is growing evidence that misalignment of miRNA expression affects tumorigenesis based on activation of either tumor suppressor or oncogene [8] [9] [10] [11] [12] . miRNA gene polymorphism affects tumor susceptibility by destroying miRNA biosynthesis and target gene expression, changing mature miRNA, or by affecting its interaction with target genes [13] [14] [15] [16] . The relationship between miRNA gene polymorphisms is complicated. For example, in each case, the rs11614913 variant homozygote CC was associated with increased cancer risk. Risk of developing oesophageal cancer in Caucasian males and never-smokers was significantly associated with the rs11614913 variant homozygote TT, the minor allele in this population [17] . Rs11614913 is located on the 3' passenger (3p) strand mature sequence of mir-196a-2, thereby possibly affecting both maturation and the repertoire of target mRNAs with which it interacts. Indeed, previous studies have shown that sequence variations in mature and precursor miRNA sequences affect miRNA biogenesis [18, 19] , and levels of mature miR-196a-2 were lower in CC carriers than in TT carriers [20, 21] . Notably, this SNP has also been associated with poor survival in patients with lung cancer.
The miR-34 family members include miR-34a, miR-34b, and miR-34c. miR-34a is encoded by its own transcription, while the miR-34b and miR-34c share a primary transcription (pri-miR-34b/c) [22] . In the promoter region of Pri-miR-34b/c, a potentially functional rs4938723 T/C variant may affect the binding of transcription factor Gata-X, thereby changing the expression of pri-miR-34b/c [23] [24] [25] . The rs4938723 T>C variant may potentially influence the expression of miR-34b/c via genetic and epigenetic mechanisms, leading to increased or decreased risk of cancer. Previous studies proposed that miR-34b/c is dysregulated in various cancers [26] [27] [28] .
111 irrelevant articles were excluded after reading the abstract and 59 papers were left for full articlc cvaluation Duplication 3 Meta-analysis or systematic reviev 25 Another polymorphism in the same miRNA (miR-34b, rs2187473) 2 Fianally, 29 different articles with 30 case-control studies about pri-miR-34b/c rs4938723 polymorphism and whole cancer susceptibility were included in our meta-analysis Similar to other kinds of polymorphisms, miR-34b/c rs4938723 polymorphism may influence its own expression, then affect its target genes' expression, finally promoting or inhibiting translation of target proteins to act on several biological functions. For example, Tong (2016) [29] reported rs4938723 CC genotype was significantly associated with reduced lymphoblastic leukemia risk, and C-allele may increase the transcription activity of miR-34b/c. However, Chen (2016) [30] found that TC+CC genotype was correlated with an increased risk of hepatocellular carcinoma compared to the TT genotype, which disagrees with Tong's results. In addition, Zhu (2015) [31] indicated no association between this polymorphism and esophageal squamous cell carcinoma.
A number of meta-analyses with respect to association between this polymorphism and cancer susceptibility have been reported, but with some limitations and false-positive conclusions. Li (2017) [32] indicated a rs4938723 polymorphism HWE -Hardy-Weinberg equilibrium; HB -hospital-based; PB -population-based; PCR-FLIP -polymerase chain reaction and restrictive fragment length polymorphism; MALDI-TOF-MS -matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; DHPLC -denaturing high performance liquid chromatography; LDR -ligation detection reaction. had a significant relationship with the whole cancer risk. In addition, this polymorphism played an increased risk in hepatocellular carcinoma, but a decreased risk for colorectal, gastric, and esophageal squamous cell cancer. Furthermore, Wang (2014) [33] suggested that this polymorphism may be associated with the risk of various types of cancers, including nasopharyngeal cancer, osteosarcoma, and renal cell cancer, especially in Asians. In addition to these 2 meta-analyses, some vital case-control studies were included, and some novel studies were also reported. We considered that it was necessary to re-analyze all case-control studies to assess the association between rs4938723 variant and tumor susceptibility [22, 25, [29] [30] [31] . Overall ((I-squared=76.5%, p=0.000) NOTE: Weights are from random effects analysis Asian Yuan (2016) Gao (2013) OH (2014) Yiu (2013) Zhu (2015) Zhang (2014) You (2011) Bulibu (2018) Yang (2014) Pan (2015) Wu (2017) Han (2013) Xu (2011) Chen (2016) Liu (2017) Son (2013) Pu (2012 Table 2 . Total and stratified subgroup analysis for pri-miR-34b/c rs4938723 polymorphism site and cancer susceptibility.
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Material and Methods
Identification strategy
We searched in PubMed, EMbase, Web of Science, CNKI, VIP, and WanFang databases (updated on Sep 10, 2018) using 'polymorphism' or 'variant' or 'single-nucleotide polymorphism (SNP)' or 'mutation', 'cancer' or 'tumor', and 'miR-34b/c' or 'primiR-34'. Each publication that assessed the relationship between rs4938723 polymorphism and cancer risk was collected.
Search criterion
The selection criteria were: (1) evaluation of pri-miR-34b/c rs4938723 and all types of cancer risks, (2) case-control design, and (3) available genotype frequency. Exclusion criteria were: (1) studies with duplicate data (the most recent or complete study with the largest number of cases and controls were included), and (2) studies that have not yet been published.
Data extraction
The following data were collected: first author, year of publication, race of origin, cancer type by traditional classification, cancer type by our own standard, sample size (cases/controls), each kind of genotype both for case and control groups, study design (HB: hospital-based and PB: population-based), source of control, Hardy-Weinberg equilibrium (HWE) of controls, and genotyping method.
Statistical analysis
Odds ratio (OR) with 95% confidence interval (CI) was used to measure the strength of the association between pri-miR-34b/c rs4938723 and cancers. We analyzed this correlation by using 5 different genetic models: C-allele vs. T-allele, CC vs. TT, CT vs. TT, CC+CT vs. TT, and CC vs. CT+TT. Ethnicity subgroup were categorized as Caucasian, Asian, African, or mixed (if study population was not a pure race). We divided the control group into 4 classes based on source: HB or PB. In the cancer type subgroup, we included hepatocellular carcinoma, leukemia, colorectal cancer, gastric cancer, breast cancer, esophageal cancer, digestive cancer, female specific cancer, and other cancers (if not in the above types).
Heterogeneity assumption was assessed with a chi-square-based Q-test. The statistical significance was calculated with the Z-test.
When P for the heterogeneity test (Ph) was more than 0.10, the fixed-effects model was applied; otherwise, the random-effects model was used [58, 59] . The funnel plot asymmetry and publication bias were evaluated by both Egger's test and Begg's test [60, 61] . under HWE was evaluated in controls using the Pearson chi-square test. All these statistical tests were performed using Stata software (version 11.0; StataCorp LP, College Station, TX).
Results
Study characteristics
After reviewing the title, abstract, and full text, we excluded meta-analyses, reviews, case-only studies, and other gene polymorphisms. The flowchart illustrating the search strategy is shown in Figure 1 . Finally, 29 different papers describing 30 casecontrol studies [22, 25, [29] [30] [31] evaluating the relationship between rs4938723 polymorphism and cancer were identified. Study characteristics are shown in Table 1 . The HWE in controls was consistent with 0.05, except for 1 study by [30] .
To observe a representation of our analysis, we investigated the minor allele frequency from 5 main worldwide populations in the 1000 Genomes Browser: East Asian, 0.305; European, 0.365; African, 0.276; American, 0.219; and South Asian, 0.244 (Figure 2 ).
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Indexed Figure 6 . Forest plot of colorectal and esophageal cancer risk associated with pri-miR-34b/c rs4938723 polymorphism (CC vs. CT+TT).
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
None of the control populations had a history of malignant diseases. Genotyping methods are listed in Table 1 .
Quantitative synthesis
Total analysis
In the total group, no vital relationship was found in all comparisons (e.g., C-allele vs. T-allele: OR=1.04; 95% CI=0.97-1.13; P (heterogeneity) <0.001, Figure 3 ). At the same time, if we excluded 1 paper that was not consistent with HWE, a similar association was detected (Table 2 ). In addition, no association was detected in subgroup analysis based on ethnicity and source of control (Table 2) .
Subgroup analysis by cancer type
Detailed results are shown in Table 2 . Statistically significant relationships were observed between pri-miR-34b/c rs4938723 and risk of 4 types of cancers: as a risk factor for hepatocellular carcinoma (e.g., CC vs. TT: OR=1.53; 95% CI=1.04-2.23; P (heterogeneity) <0.001, Figure 4 ), but as a protective factor for 7066 Figure 7 . Forest plot of cancer risk associated with pri-miR-34b/c rs4938723 polymorphism (CC vs. CT+TT) in the age subgroup. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
leukemia (e.g., CC vs. TT: OR=0.52; 95% CI=0.34-0.79; P (heterogeneity) =0.411 for heterogeneity, Figure 5 ), colorectal cancer (CC vs. CT+TT: OR=0.67; 95% CI=0.48-0.93; P (heterogeneity) =0.519 for heterogeneity, Figure 6 ), and esophageal cancer (CC vs. CT+TT: OR=0.76; 95% CI=0.63-0.91; P (heterogeneity) =0.251 for heterogeneity, Figure 6 ) ( Table 2) .
Subgroup analysis by age and other kinds of analysis
Interestingly, in the age subgroup, decreased associations were found both in <62 (OR=0.70; 95% CI=0.50-0.98; P (heterogeneity) =0.654 for heterogeneity) and ³62 groups (OR=0.68; 95% CI=0.50-0.93; P (heterogeneity) =0.942 for heterogeneity) ( Figure 7 , Table 2 ). No association was detected in subgroups based on sex, smoking status, and drinking (Table 2) .
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Relationships between rs4938723 polymorphism and prognosis of cancer
To our regret, no association between this polymorphism and cancer prognosis in 2 models (localized and advanced) (CC+CT vs. TT: OR=1.15; 95% CI=0.91-1.46; P (heterogeneity) =0.735 for heterogeneity, P=0.237 for Z-test) was found (Table 3) . (Table 4) . Despite the above results, each study reflected the influence of the individual dataset on the pooled OR, and observed that the corresponding pooled OR was not significantly altered, indicating that our results were statistically robust (for example: allelic contrast, Figure 10 ). Discussion mir-34b/c gene is part of the p53 pathway and enhances its tumor suppressor activities [62, 63] ; it transcribes microRNA-34 b and c, which inhibit p53 antagonists [64] , cyclin-dependent kinases, and pro-apoptotic proteins [65] . The deregulation of miR-34b/c was observed in several carcinoma cells, and cell proliferation, apoptosis, migration, and invasion were involved. Recently, a SNP located at the promoter region of mir-34b/c gene (rs4938723T/C) was identified, and its role in tumorigenesis has been widely investigated, as it can alter miR-34b/c transcription levels, because it can affect GATA-X binding. Presence of C in this location leads to binding to the GATA-X [33] .
Publication bias diagnosis and sensitivity analysis
Our meta-analysis explored the association between pri-miR34b/c rs4938723 and overall cancer susceptibility, involving 13 950 cancer cases and 16 071 controls. The main results of our analysis are that this polymorphism has different associations with different types of cancer: increased association for hepatocellular carcinoma, but decreased association for leukemia, colorectal, and esophageal cancer. The following reasons may explain these results. First, differences in the distribution of various cancers between cases and controls might be a source of variability during pooling. Second, rs4938723 polymorphism might carry out different functions in different types of cancers. Third, because cancer is a multi-factorial disease caused by the complex interactions between many genetic and environmental factors, there is no single gene or environmental factor that has a significant effect on cancer susceptibility [66] . The present study differs from previous meta-analyses in that we included some environmental and clinical factors, such as sex, smoking status, age, drinking, and prognosis of cancer. Of note, a positive association was found in the age subgroup. Our results were also different from those of previous metaanalyses [32, 33] because previously there had been no association between this polymorphism and the whole cancer risk, as well as no association for Asians and gastric cancer risk. This was because the relatively small samples in previous analysis resulted in false-positive results. So, it made sense to recombine all studies to gain a comprehensive and credible conclusion, and to correct error at the same time.
Some limitations should be considered. First, sample sizes varied widely in the different studies (range of the number of cases/controls: 110/120 to 1109/1275), which may increase the publication bias. Second, there were only 2 case-control studies regarding leukemia, colorectal, and gastric cancer; future studies should also focus on these types of cancers. Third, few studies used mixed, Caucasian, or African populations; future studies should also focus on these races. Fourth, (2017) Chen (2015) 1.00 additional studies are needed to address the effects of race and sample size on the predicted associations, and more attention must be placed on gene-gene and gene-environment interactions. Fifth, other environmental factors, such as dietary factors and infectious agents, increase the load of carcinogenic substances humans are exposed to.
